Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 10;13(1):299.
doi: 10.1186/s13071-020-04171-6.

Amaryllidaceae alkaloids with anti-Trypanosoma cruzi activity

Affiliations

Amaryllidaceae alkaloids with anti-Trypanosoma cruzi activity

Nieves Martinez-Peinado et al. Parasit Vectors. .

Abstract

Background: Chagas disease, caused by the protozoan Trypanosoma cruzi, is a neglected disease that affects ~7 million people worldwide. Development of new drugs to treat the infection remains a priority since those currently available have frequent side effects and limited efficacy at the chronic stage. Natural products provide a pool of diversity structures to lead the chemical synthesis of novel molecules for this purpose. Herein we analyzed the anti-T. cruzi activity of nine alkaloids derived from plants of the family Amaryllidaceae.

Methods: The activity of each alkaloid was assessed by means of an anti-T. cruzi phenotypic assay. We further evaluated the compounds that inhibited parasite growth on two distinct cytotoxicity assays to discard those that were toxic to host cells and assure parasite selectivity.

Results: We identified a single compound (hippeastrine) that was selectively active against the parasite yielding selectivity indexes of 12.7 and 35.2 against Vero and HepG2 cells, respectively. Moreover, it showed specific activity against the amastigote stage (IC50 = 3.31 μM).

Conclusions: Results reported here suggest that natural products are an interesting source of new compounds for the development of drugs against Chagas disease.

Keywords: Alkaloids; Amaryllidaceae; Chagas disease; Cytotoxicity; Hippeastrine; Phenotypic assays; Trypanosoma cruzi.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Chemical structures of the alkaloids evaluated in this study
Fig. 2
Fig. 2
Quality controls of the T. cruzi growth inhibition assay (a, b), toxicity assay with Vero cells (c, d) and toxicity assay with HepG2 cells (e, f). Z’-values for each of the rounds launched are represented on the left (a, c, e); dashed line marks the 0.5 threshold. IC50 and TC50 values of the reference drugs BNZ and DTX are represented on the right (b, d, f); continuous lines indicate the average values, whereas the dashed lines indicate ± 3 SD limits
Fig. 3
Fig. 3
Anti-T.cruzi phenotypic assay dose-response curves. Graphs represent mean results and SD of at least three biological replicates
Fig. 4
Fig. 4
Dose-response curves obtained from the Vero and HepG2 cell toxicity assays. Vero cells toxicity assays are represented by circles and straight lines while HepG2 cell toxicity assays are represented by triangles and dashed lines. Graphs represent mean results and SD of at least three biological replicates
Fig. 5
Fig. 5
Anti-amastigote dose response curves of hippeastrine and BNZ. Graphs represent mean results and SD of at least three replicates

References

    1. WHO. Chagas disease (American trypanosomiasis). https://www.who.int/en/news-room/fact-sheets/detail/chagas-disease-(amer...). Accessed 4 Mar 2020.
    1. Pinazo MJ, Gascon J. Chagas disease: from Latin America to the world. Reports Parasitol. 2015;4:7–14.
    1. Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis. 2001;1:92–100. - PubMed
    1. Alonso-Padilla J, Gállego M, Schijman AG, Gascon J. Molecular diagnostics for Chagas disease: up to date and novel methodologies. Expert Rev Mol Diagn. 2017;17:699–710. - PubMed
    1. Crespillo-Andujar C, Venanzi-Rullo E, López-Vélez R, Monge-Maillo B, Norman F, López-Polín A, et al. Safety profile of benznidazole in the treatment of chronic Chagas disease: experience of a referral centre and systematic literature review with meta-analysis. Drug Saf. 2018;41:1035–1048. - PubMed